For a century, nephrosclerosis was ascribed to nonmalignant hypertension and aging. However, it was intuitively perceived that hypertension may follow rather than explain this nephrovasculopathy. Hypertensive nephrosclerosis was long considered a major cause of end-stage renal failure (ESRD). This is especially true in blacks of African descent but not in other ethnic populations. The term ‘nephrosclerosis' is still an easy way out to classify a patient with renal insufficiency. This leads to neglect the possibility of an overlooked nephropathy complicated by hypertension and to believe that drastic blood pressure control may retard the progression to ESRD. Several clinical and experimental lines of evidence lead to the understanding that nephrosclerosis, especially in blacks, is a genetic renovasculopathy that precedes the rise in blood pressure. The identification of coding region variants in APOL1 encoding apolipoprotein L-1 in black but also white and Asians opens new lines of research on the genetics of nephroangiosclerosis and of FSGS. Metabolic derangements, such as obesity, oxidative stress, dyslipidemia and atherosclerosis may be considered confounding factors with regard to nephrosclerosis. Histomorphometric studies led to sorting out the lesions due to aging from those stemming from hypertension. They shed new light not only on glomerular lesions that comprise ischemic obsolescence but also on glomerulomegaly and focal-segmental sclerosis, the latter due to a loss of renal autoregulation. It appears that the control of hypertension is not credited with the expected benefit for slowing the decline of renal function. ‘Nephrosclerosis' can be considered an umbrella term of poor significance that should be replaced by its pathologic description, that is, arterionephrosclerosis and incite to elucidate the various genetic and metabolic factors that lead to a lesion in quest of a specific disease.

1.
Fahr T: Über Nephrosklerose. Virchows Arch (Pathol Anat) 1919;26:119-178.
2.
Heidland A, Gerabek W, Sebekova K: Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension. J Hum Hypertens 2001;15:5-16.
3.
Shevchenko YL, Tsitlik JE: 90th Anniversary of the development by Nikolai S. Korotkoff of the auscultatory method of measuring blood pressure. Circulation 1996;94:116-118.
4.
Goldblatt H: Hypertension and vascular disease. Circulation 1960;21:643-645.
5.
Papper S: Nephrosclerosis; in Strauss MB, Welt LG (eds): Diseases of the Kidney. Boston, Little, Brown and Co, 1963, chapter 15, pp 501-525.
6.
Heptinstall RH: Pathology of the kidney, ed 3. Little, Brown and Co, 1983, chapter 5, vol 1, pp 181-246.
7.
Fogo A, Breyer JA, Smith MC, et al: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997;51:244-252.
8.
Kopp JB: Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens 2013;22:266-272.
9.
Griffin KA, Kramer H, Bidani AK: Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008;294:F685-F696.
10.
Grobe JL, Rahmouni K: The adipose/circulating renin-angiotensin system cross-talk enters a new dimension. Hypertension 2012;60:1389-1390.
11.
Kasiske BL: Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int 1987;31:1153-1159.
12.
Farris AB, Colvin RB: Renal interstitial fibrosis: mechanisms and evaluation. Curr Opin Nephrol Hypertens 2012;21:289-300.
13.
Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008;74:867-872.
14.
Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Am Soc Nephrol 2006;17:17-25.
15.
Higgins DF, Kimura K, Bernhardt WM, et al: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007;117:3810-3820.
16.
Neusser MA, Lindenmeyer MT, Moll AG, et al: Human nephrosclerosis triggers a hypoxia-related glomerulopathy. Am J Pathol 2010;176:594-607.
17.
Haase VH: Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair 2012;5(suppl 1):S16.
18.
Haase VH: Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int 2009;76:492-499.
19.
Just A: Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol 2007;292:R1-R17.
20.
Bidani AK, Schwartz MM, Lewis EJ: Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol 1987;252:F1003-F1010.
21.
Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA: Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 2013;22:1-9.
22.
Pelayo JC, Westcott JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 1991;88:101-105.
23.
Griffin KA, Picken M, Bidani AK: Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 1994;4:2023-2031.
24.
Hayashi K, Epstein M, Loutzenhiser R, Forster H: Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992;2:1578-1586.
25.
Takenaka T, Forster H, De Micheli A, Epstein M: Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ Res 1992;71:471-480.
26.
Wang X, Ajikobi DO, Salevsky FC, Cupples WA: Impaired myogenic autoregulation in kidneys of Brown Norway rats. Am J Physiol Renal Physiol 2000;278:F962-F969.
27.
Van Dokkum RP, Sun CW, Provoost AP, et al: Altered renal hemodynamics and impaired myogenic responses in the fawn-hooded rat. Am J Physiol 1999;276:R855-R863.
28.
Kimura K, Tojo A, Hirata Y, et al: Morphometric analysis of renal arterioles in subtotally nephrectomized rats. J Lab Clin Med 1993;122:273-283.
29.
Iversen BM, Amann K, Kvam FI, et al: Increased glomerular capillary pressure and size mediate glomerulosclerosis in SHR juxtamedullary cortex. Am J Physiol 1998;274:F365-F373.
30.
Christensen PK, Hommel EE, Clausen P, et al: Impaired autoregulation of the glomerular filtration rate in patients with nondiabetic nephropathies. Kidney Int 1999;56:1517-1523.
31.
Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995;96:793-800.
32.
Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998;9:2096-2101.
33.
Smeda JS, Lee RM, Forrest JB: Prenatal and postnatal hydralazine treatment does not prevent renal vessel wall thickening in SHR despite the absence of hypertension. Circ Res 1988;63:534-542.
34.
Bridoux F, Hazzan M, Pallot JL, et al: Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis. Nephrol Dial Transplant 1992;7:100-104.
35.
Meyrier A: Nephrosclerosis: update on a centenarian. Nephrol Dial Transplant 2014;pii:gfu366.
36.
Hill GS, Heudes D, Bariéty J: Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 2003;63:1027-1036.
37.
Hill GS, Heudes D, Jacquot C, Gauthier E, Bariéty J: Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int 2006;69:823-831.
38.
Hill GS: Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008;17:266-270.
39.
Tracy RE: Renovasculopathies of hypertension and the rise of blood pressure with age in blacks and whites. Semin Nephrol 1996;16:126-133.
40.
Tracy RE, Bhandaru SY, Oalmann MC, Guzman MA, Newmann WP 3rd: Blood pressure and nephrosclerosis in black and white men and women aged 25 to -54. Mod Pathol 1991;4:602-609.
41.
Tracy RE, Malcom GT, Oalmann MC, Qureshi U, Ishii T, Velez-Duran M: Renal microvascular features of hypertension in Japan, Guatemala, and the United States. Arch Pathol Lab Med 1992;116:50-55.
42.
Tracy RE, Guzman MA, Oalmann MC, Newman WP 3rd, Strong JP: Nephrosclerosis in three cohorts of Black and White men born 1925 to 1944, 1934 to 1953, and 1943 to 1962. Am J Hypertens 1993;6:185-192.
43.
Kopp JB, Smith MW, Nelson GW, et al: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175-1184.
44.
Genovese G, Friedman DJ, Ross MD, et al: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841-845.
45.
Madhavan SM, O'Toole JF, Konieczkowski M, et al: APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011;22:2119-2128.
46.
Lipkowitz MS, Freedman BI, Langefeld CD, et al: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013;83:114-120.
47.
Chang J, Ma JZ, Zeng Q, et al: Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol 2013;304:F348-F355.
48.
Schlessinger SD, Tankersley MR, Curtis JJ: Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994;23:655-660.
49.
Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995;25:207-221.
50.
Meyrier A, Simon P: Nephroangiosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant 1996;11:2116-2120.
51.
Murea M, Freedman BI: Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010;19:235-241.
52.
Skorecki KL, Wasser WG: Hypertension-misattributed kidney disease in African Americans. Kidney Int 2013;83:6-9.
53.
Hsu CY: Does non-malignant hypertension cause renal insufficiency? Evidence-based perspective. Curr Opin Nephrol Hypertens 2002;11:267-272.
54.
Wright JT Jr, Bakris G, Greene T, et al: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-2431.
55.
Parsa A, Kao WH, Xie D, et al: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013;369:2183-2196.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.